FDA approves Reclast for osteoporosis care

Share this content:
FDA approves Reclast for osteoporosis care
FDA approves Reclast for osteoporosis care
The drug Reclast has just been approved by the Food & Drug Administration for a new purpose: the treatment and prevention of osteoporosis. Specifically, patients expected to be on glucocorticoids, or steroids, for at least 12 months can now use it.
http://www.novartis.com/